FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2801832078> ?p ?o ?g. }

• W2801832078 endingPage "605" @default.
• W2801832078 startingPage "594" @default.
• W2801832078 abstract "<b><i>Background/Aims:</i></b> Chronic hepatitis C (HCV) virus infection reactivates under immunosuppressive drugs and therefore has a negative impact on long-term survival of kidney transplant recipients. Treatment-induced clearance of hepatitis C virus (HCV) in kidney transplant candidates prevents virus reactivation after transplantation. Paritaprevir/Ritonavir/Ombitasvir with Dasabuvir (PrOD) represents a highly effective treatment regimen for HCV genotype 1 (GT1), also suitable for patients with end-stage renal disease (ESRD). Serious drug-drug interactions may represent a limiting factor of this regimen. The aim of this retrospective study was to evaluate safety, efficacy and drug-drug interactions management associated with PrOD treatment in the Czech real-world cohort. <b><i>Methods:</i></b> Emphasizing concomitant medication adjustment, we described the treatment course with PrOD regimen in 23 patients (4 with CKD4 and 19 on maintenance haemodialysis) infected with HCV GT1 (21 GT1b, 2 GT1a), 18 males and 5 females with an average age of 53.7 years. Six patients had compensated liver cirrhosis and 3 of them were liver transplant recipients. <b><i>Results:</i></b> All 23 patients completed the 12-week treatment and achieved sustained virological response 12 weeks after the treatment (SVR12 rate 100%). None of the patients presented with a significant decrease in haemoglobin level, white blood cell and platelet count during the treatment period. The most frequent adverse events were nausea, hypotension, diarrhoea, and hyperkalemia. Four patients presented with a serious adverse event unrelated to the antiviral drugs (salmonellosis, non-functional kidney graft rejection, early gastric cancer, renal cyst infection, initiation of haemodialysis). Concomitant medication had to be modified with the treatment initiation in 10 out of 23 (43.5%) patients (calcium channel blockers, ACE inhibitors, statins, diuretics, tacrolimus); four patients required further adjustment of antihypertensive drugs or tacrolimus dosage on-treatment. <b><i>Conclusion:</i></b> PrOD regimen demonstrated an excellent efficacy and good tolerability. Both prospective adjustment of concomitant medication and further on-treatment adjustment allowed for a safe treatment course." @default.
• W2801832078 created "2018-05-17" @default.
• W2801832078 creator A5002031373 @default.
• W2801832078 creator A5009214471 @default.
• W2801832078 creator A5015910778 @default.
• W2801832078 creator A5069569458 @default.
• W2801832078 creator A5078806992 @default.
• W2801832078 creator A5088381041 @default.
• W2801832078 date "2018-01-01" @default.
• W2801832078 modified "2023-10-18" @default.
• W2801832078 title "Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Regimen in the Treatment of Genotype 1 Chronic Hepatitis C Infection in Patients with Severe Renal Impairment and End-Stage Renal Disease: a Real-Life Cohort" @default.
• W2801832078 cites W1869921580 @default.
• W2801832078 cites W1908153784 @default.
• W2801832078 cites W1941458012 @default.
• W2801832078 cites W1973675889 @default.
• W2801832078 cites W1980380351 @default.
• W2801832078 cites W1982967737 @default.
• W2801832078 cites W1992766050 @default.
• W2801832078 cites W2024966589 @default.
• W2801832078 cites W2043193067 @default.
• W2801832078 cites W2082154943 @default.
• W2801832078 cites W2113428683 @default.
• W2801832078 cites W2113636405 @default.
• W2801832078 cites W2144953406 @default.
• W2801832078 cites W2174985448 @default.
• W2801832078 cites W2290250957 @default.
• W2801832078 cites W2296452901 @default.
• W2801832078 cites W2315634424 @default.
• W2801832078 cites W2326966321 @default.
• W2801832078 cites W2513878057 @default.
• W2801832078 cites W2519434695 @default.
• W2801832078 cites W2567208426 @default.
• W2801832078 cites W2579688015 @default.
• W2801832078 cites W2587025365 @default.
• W2801832078 cites W2587472693 @default.
• W2801832078 cites W2594758046 @default.
• W2801832078 cites W2602388647 @default.
• W2801832078 cites W342696137 @default.
• W2801832078 cites W4210961054 @default.
• W2801832078 cites W4211243282 @default.
• W2801832078 cites W4241616429 @default.
• W2801832078 doi "https://doi.org/10.1159/000488965" @default.
• W2801832078 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29669332" @default.
• W2801832078 hasPublicationYear "2018" @default.
• W2801832078 type Work @default.
• W2801832078 sameAs 2801832078 @default.
• W2801832078 citedByCount "20" @default.
• W2801832078 countsByYear W28018320782018 @default.
• W2801832078 countsByYear W28018320782019 @default.
• W2801832078 countsByYear W28018320782021 @default.
• W2801832078 countsByYear W28018320782022 @default.
• W2801832078 countsByYear W28018320782023 @default.
• W2801832078 crossrefType "journal-article" @default.
• W2801832078 hasAuthorship W2801832078A5002031373 @default.
• W2801832078 hasAuthorship W2801832078A5009214471 @default.
• W2801832078 hasAuthorship W2801832078A5015910778 @default.
• W2801832078 hasAuthorship W2801832078A5069569458 @default.
• W2801832078 hasAuthorship W2801832078A5078806992 @default.
• W2801832078 hasAuthorship W2801832078A5088381041 @default.
• W2801832078 hasBestOaLocation W28018320781 @default.
• W2801832078 hasConcept C126322002 @default.
• W2801832078 hasConcept C142462285 @default.
• W2801832078 hasConcept C203014093 @default.
• W2801832078 hasConcept C2522874641 @default.
• W2801832078 hasConcept C2776408679 @default.
• W2801832078 hasConcept C2776455275 @default.
• W2801832078 hasConcept C2777100407 @default.
• W2801832078 hasConcept C2778785139 @default.
• W2801832078 hasConcept C2778867932 @default.
• W2801832078 hasConcept C2779298103 @default.
• W2801832078 hasConcept C2780040827 @default.
• W2801832078 hasConcept C2781413609 @default.
• W2801832078 hasConcept C2993143319 @default.
• W2801832078 hasConcept C71924100 @default.
• W2801832078 hasConcept C90924648 @default.
• W2801832078 hasConceptScore W2801832078C126322002 @default.
• W2801832078 hasConceptScore W2801832078C142462285 @default.
• W2801832078 hasConceptScore W2801832078C203014093 @default.
• W2801832078 hasConceptScore W2801832078C2522874641 @default.
• W2801832078 hasConceptScore W2801832078C2776408679 @default.
• W2801832078 hasConceptScore W2801832078C2776455275 @default.
• W2801832078 hasConceptScore W2801832078C2777100407 @default.
• W2801832078 hasConceptScore W2801832078C2778785139 @default.
• W2801832078 hasConceptScore W2801832078C2778867932 @default.
• W2801832078 hasConceptScore W2801832078C2779298103 @default.
• W2801832078 hasConceptScore W2801832078C2780040827 @default.
• W2801832078 hasConceptScore W2801832078C2781413609 @default.
• W2801832078 hasConceptScore W2801832078C2993143319 @default.
• W2801832078 hasConceptScore W2801832078C71924100 @default.
• W2801832078 hasConceptScore W2801832078C90924648 @default.
• W2801832078 hasIssue "2" @default.
• W2801832078 hasLocation W28018320781 @default.
• W2801832078 hasOpenAccess W2801832078 @default.
• W2801832078 hasPrimaryLocation W28018320781 @default.
• W2801832078 hasRelatedWork W2193729855 @default.
• W2801832078 hasRelatedWork W2324515674 @default.
• W2801832078 hasRelatedWork W2399748013 @default.
• W2801832078 hasRelatedWork W2626697548 @default.

• next